{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:03:33Z","timestamp":1791497013022,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24 GM129541"],"award-info":[{"award-number":["U24 GM129541"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001061","name":"Rebecca L Cooper Medical Research Foundation","doi-asserted-by":"publisher","award":["PG2019449"],"award-info":[{"award-number":["PG2019449"]}],"id":[{"id":"10.13039\/501100001061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ymthe.2023.03.032","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T01:58:33Z","timestamp":1680487113000},"page":"1979-1993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9365-342X","authenticated-orcid":false,"given":"Grant J.","family":"Logan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mietzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Khandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"D\u2019Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mawj","family":"Mandwie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Goodnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne H.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian E.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.03.032_bib1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.03.032_bib2","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.03.032_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2015.07.006","article-title":"Adeno-associated virus serotypes for gene therapeutics","volume":"24","author":"Lisowski","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jnc.13861","article-title":"Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells","volume":"140","author":"Merkel","year":"2017","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2023.03.032_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV capsid to evade immune responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/v11040362","article-title":"Twenty-five years of structural parvovirology","volume":"11","author":"Mietzsch","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2023.03.032_bib7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.03.032_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2023.03.032_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.33","article-title":"B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Molecular therapy","volume":"1","author":"Corti","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.03.032_bib11","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41598-020-57893-z","article-title":"Capsid-specific removal of circulating antibodies to adeno-associated virus vectors","volume":"10","author":"Bertin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.03.032_bib12","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.03.032_bib13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/gt.2016.11","article-title":"Exosome-associated AAV vector as a robust and convenient neuroscience tool","volume":"23","author":"Hudry","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2023.03.032_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1704766114","article-title":"Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion","volume":"114","author":"Tse","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.03.032_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01251-21","article-title":"Structurally mapping antigenic epitopes of adeno-associated virus 9: development of antibody escape variants","volume":"96","author":"Emmanuel","year":"2022","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01249-21","article-title":"Structural study of Aavrh.10 receptor and antibody interactions","volume":"95","author":"Mietzsch","year":"2021","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01011-18","article-title":"Mapping an adeno-associated virus 9-specific neutralizing epitope to develop next-generation gene delivery vectors","volume":"92","author":"Giles","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/vim.2020.0022","article-title":"Parvovirus capsid-antibody complex structures reveal conservation of antigenic epitopes across the family","volume":"34","author":"Emmanuel","year":"2021","journal-title":"Viral Immunol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00976-20","article-title":"Coevolution of adeno-associated virus capsid antigenicity and tropism through a structure-guided approach","volume":"94","author":"Havlik","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01394-18","article-title":"High-resolution structural characterization of a new adeno-associated virus serotype 5 antibody epitope toward engineering antibody-resistant recombinant gene delivery vectors","volume":"93","author":"Jose","year":"2019","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib21","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/nprot.2013.117","article-title":"Isolation of human monoclonal antibodies from peripheral blood B cells","volume":"8","author":"Huang","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2023.03.032_bib22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fimmu.2016.00410","article-title":"Evaluation of the antigen-experienced B-cell receptor repertoire in healthy children and adults","volume":"7","author":"IJspeert","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib23","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1038\/cti.2016.42","article-title":"Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing","volume":"5","author":"Vigdorovich","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jviromet.2016.07.009","article-title":"Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies","volume":"236","author":"Tseng","year":"2016","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.ymthe.2023.03.032_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","article-title":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec. Molecular therapy","volume":"21","author":"Day","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.03.032_bib27","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","article-title":"Cutting edge: long-term B cell memory in humans after smallpox vaccination","volume":"171","author":"Crotty","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nature06890","article-title":"Rapid cloning of high-affinity human monoclonal antibodies against influenza virus","volume":"453","author":"Wrammert","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.03.032_bib29","doi-asserted-by":"crossref","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2023.03.032_bib30","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2023.03.032_bib31","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3389\/fimmu.2020.01135","article-title":"Isolating human monoclonal antibodies against adeno-associated virus from donors with\u00a0pre-existing immunity","volume":"11","author":"Giles","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.omtm.2020.10.001","article-title":"Characterization of AAV-specific affinity ligands: consequences for vector purification and development strategies. Molecular therapy","volume":"19","author":"Mietzsch","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.03.032_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00335-22","article-title":"Characterization of the serpentine adeno-associated virus (SAAV) capsid structure: receptor interactions and antigenicity","volume":"96","author":"Mietzsch","year":"2022","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib34","doi-asserted-by":"crossref","first-page":"7326","DOI":"10.1128\/JVI.00448-12","article-title":"Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid","volume":"86","author":"Bell","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02213-17","article-title":"An alternate route for adeno-associated virus (AAV) entry independent of AAV receptor","volume":"92","author":"Dudek","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.omtm.2022.05.009","article-title":"Structural basis for the neurotropic AAV9 and the engineered AAVPHP.eB recognition with cellular receptors","volume":"26","author":"Xu","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.03.032_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.753467","article-title":"Adeno-associated viruses (AAV) and host immunity - a race between the hare and the hedgehog","volume":"12","author":"Rapti","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib38","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1093\/nar\/gkh593","article-title":"Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line","volume":"32","author":"Mohammadi","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2023.03.032_bib39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","article-title":"Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity","volume":"76","author":"Rabinowitz","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba3312","article-title":"Restoring the natural tropism of AAV2 vectors for human liver","volume":"12","author":"Cabanes-Creus","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.03.032_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/JVI.72.1.309-319.1998","article-title":"Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2","volume":"72","author":"Rutledge","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib42","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.03.032_bib43","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of Adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib44","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","article-title":"Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus","volume":"72","author":"Xiao","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gt.2009.157","article-title":"High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency","volume":"17","author":"Ayuso","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2023.03.032_bib46","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/gt.2012.67","article-title":"Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes","volume":"20","author":"Dane","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2023.03.032_bib47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-1-4939-8648-4_15","article-title":"Sequencing and affinity determination of antigen-specific B lymphocytes from peripheral blood","volume":"1827","author":"Schofield","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2023.03.032_bib48","first-page":"695","article-title":"IMGT\/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T\u00a0cell receptor (TR) nucleotide sequences","volume":"2011","author":"Giudicelli","year":"2011","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.ymthe.2023.03.032_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nprot.2017.126","article-title":"Transient expression of human antibodies in mammalian\u00a0cells","volume":"13","author":"Vazquez-Lombardi","year":"2018","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2023.03.032_bib50","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J.\u00a0Comput. Chem."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162300165X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162300165X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:06:51Z","timestamp":1761502011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162300165X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S152500162300165X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.032","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}